Clinical Trial Update: Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating pan-genotypic direct-acting antiviral therapy in donor HCV-positive to recipient HCV-negative lung transplant; status terminat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Respiratory Failure

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Respiratory Failure, Hepatitis C | Phase 4 | Status: TERMINATED | Results posted: 2023-04-25